Clinical Reference · Updated 2026-05-08

FLOW Trial Results

FLOW (NEJM 2024, PMID 38785189): 24% reduction in major kidney/CV events in T2D + CKD over median 3.4 years.

Clinical referencePubMed-linkedUpdated 2026-05-08
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Overview

FLOW (NEJM 2024, PMID 38785189): 24% reduction in major kidney/CV events in T2D + CKD over median 3.4 years.

PubMed citations

Related clinical pages